Patient and Safety Review Board

Granting access to data from clinical trials sponsored by LEO Pharma shall be made for scientific purposes.

This is why the main task of the Patient and Scientific Review Board is to evaluate requests for data based on the scientific rationale behind the request.

On this site, information about the composition of the Patient and Scientific Review Board, their working procedures, and their previous decisions are made available.

a. The Patient and Scientific Review Board Charter

The Charter explains the procedures and decision making process of the Patient and Scientific Review Board.

b. Dates for Board meetings:

2020

Dates will be published during Q1.

To be evaluated at a board meeting, a complete research proposal has to have been submitted via the clinical trial disclosure mailbox at least 30 working days ahead of the meeting.